摘要：In 2024, Xiamen Biopharmaceutical Port in Haicang secured approvals for 116 Class III medical devices, with an additional 47 Class

Weekly News

1

In 2024, Xiamen Biopharmaceutical Port in Haicang secured approvals for 116 Class III medical devices, with an additional 47 Class III devices approved in Q1 2025. A total of 57 innovative and improved drug candidates have entered clinical trials, marking a flourishing phase of innovation following years of cultivation. Ranked 13th in comprehensive competitiveness in the 2024 National Biopharmaceutical Industrial Park Ranking released by China National Center for Biotechnology Development, the port has maintained a top-15 position for six consecutive years. Innovation remains the primary driver of biomedical advancement: while accelerating breakthroughs in core technologies, entities within the port are extending their innovation chains and building service platform matrices. Moving forward, Haicang will continue enhancing enabling platforms and optimizing its world-class business environment for biopharmaceutical industry growth.

2024年，位于海沧的厦门生物医药港有116个三类医疗器械获批，今年一季度，又有47个三类医疗器械获批；合计57个创新药、改良药品种进入临床试验阶段。经过多年培育，厦门生物医药港正迎来创新爆发期，创新成果百花齐放。在中国生物技术发展中心2024年发布的“全国生物医药产业园区榜单”中，厦门生物医药港位列综合竞争力第13名，已连续6年进入综合竞争力前15名。创新是生物医药产业发展的第一动力。厦门生物医药港内许多创新主体在加速核心技术攻关的同时，主动延伸创新链，构建起服务平台矩阵。未来，海沧将继续搭建和升级赋能型平台，持续优化生物医药产业发展的一流营商环境。

2

On May 19, the Management Committee of Xiamen Area of China (Fujian) Pilot Free Trade Zone (“Xiamen FTZ”) and Xi’an Giant Biogene Technology Co., Ltd. signed a strategic cooperation agreement. Founded in 2000, Giant Biogene is a high-tech enterprise focused on scientific aesthetics, owning flagship brands such as “Comfy” and “COLLGENE.” The company plans to establish its Southeast Regional HQ in Xiamen FTZ, centering on a business settlement center, manufacturing base, and cross-border trade platform to create an end-to

来源：东南沿海消息通